Physician profile
Benjamin D Ernst
NPI 1477635761
$9,216.81
in general payments reported to CMS, 2019-2025
48 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $553 · 2021: $1,359 · 2022: $1,106 · 2023: $1,630 · 2024: $1,959 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,766.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,175.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $824.93 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $793.17 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $771.60 | 2021-2025 | |
| Pfizer INC. | $757.72 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.27 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $729.15 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $564.04 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $253.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $247.73 | 2019-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $246.18 | 2021 | |
| Exact Sciences Corporation | $214.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $128.20 | 2023-2024 | |
| Axsome Therapeutics, INC. | $118.63 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $116.12 | 2022-2024 | Quviviq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.